Top

Clinical Reviews in Allergy & Immunology

Published in:

01-04-2021 | Dermatomyositis

Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis

Authors: Wanlong Wu, Li Guo, Yakai Fu, Kaiwen Wang, Danting Zhang, Wenwen Xu, Zhiwei Chen, Shuang Ye

Published in: Clinical Reviews in Allergy & Immunology | Issue 2/2021

Abstract

Anti-melanoma differentiation-associated gene 5–positive dermatomyositis (MDA5⁺ DM) is a rare autoimmune disease predominantly reported in East Asia. MDA5⁺ DM is an intractable disease with impressively high mortality due to rapid-progressive interstitial lung disease (RPILD). Other typical clinical manifestations comprise DM-specific rash (Gottron’s papules, heliotrope rash) and amyopathic/hypomyopathic muscle involvement. Multiple prognostic factors have been identified. Baseline forced vital capacity (FVC) %-based staging could serve as a simplified risk stratification system. Serum biomarkers including MDA5 Ab titers, ferritin, KL-6 levels, and CD4⁺CXCR4⁺ T cell percentage could provide additional surrogate value of ILD severity and treatment response, as well as potential predictive value for survival. Spontaneous pneumomediastinum (PNM), ground-glass opacity (GGO), and consolidation were demonstrated to be the most significant features in pulmonary high-resolution computed tomography (HRCT) findings of MDA5⁺ DM-ILD. The semi-quantitative assessment of lesions in HRCT has also been demonstrated relevant to the outcome. The current treatment of this disease is still largely empirical. Immunosuppressive treatments, i.e., “triple therapy” (combination of high-dose glucocorticoids, tacrolimus, and intravenous cyclophosphamide) and JAK inhibitor-based therapy, are the mainstream regimens for MDA5⁺ DM-ILD, supported by the recently published trials. However, more efficacious regimen with favorable safety profile and high-level evidence is still urgently demanded for patients with MDA5⁺ DM-ILD, especially those at advanced-stage. We will summarize the terminology, etiology and pathogenesis, clinical features and outcome, prognostic factors, and treatment of MDA5⁺ DM-ILD in this review.

Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, Nishikawa T, Oddis CV, Ikeda Y (2005) Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 52(5):1571–1576. https://doi.org/10.1002/art.21023CrossRefPubMed

Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, Kuwana M (2009) RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis association with rapidly progressive interstitial lung disease. Arthritis Rheum 60(7):2193–2200. https://doi.org/10.1002/art.24621CrossRefPubMed

Sontheimer RD (2002) Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 46(4):626–636. https://doi.org/10.1067/mjd.2002.120621CrossRefPubMed

Mammen AL, Allenbach Y, Stenzel W, Benveniste O, Group EtWS (2020) 239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14–16 December 2018. Neuromuscul Disord 30(1):70–92. https://doi.org/10.1016/j.nmd.2019.10.005CrossRef

Lian X, Zou J, Guo Q, Chen S, Lu L, Wang R, Zhou M, Fu Q, Ye Y, Bao C (2020) Mortality risk prediction in amyopathic dermatomyositis associated with interstitial lung disease: the FLAIR model. Chest. https://doi.org/10.1016/j.chest.2020.04.057CrossRefPubMed

Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Danko K, Dimachkie MM, Feldman BM, Torre IG, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinska M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O’Callaghan A, Song YW, Vencovsky J, Ytterberg SR, Miller FW, Rider LG, International Myositis Classification Criteria Project consortium TEr, The Juvenile Dermatomyositis Cohort Biomarker S, Repository (2017) 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76(12):1955–1964. https://doi.org/10.1136/annrheumdis-2017-211468CrossRefPubMed

Cavazzana I, Fredi M, Ceribelli A, Mordenti C, Ferrari F, Carabellese N, Tincani A, Satoh M, Franceschini F (2016) Testing for myositis specific autoantibodies: comparison between line blot and immunoprecipitation assays in 57 myositis sera. J Immunol Methods 433:1–5. https://doi.org/10.1016/j.jim.2016.02.017CrossRefPubMed

Sato S, Murakami A, Kuwajima A, Takehara K, Mimori T, Kawakami A, Mishima M, Suda T, Seishima M, Fujimoto M, Kuwana M (2016) Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies. PLoS ONE 11(4):e0154285. https://doi.org/10.1371/journal.pone.0154285CrossRefPubMedPubMedCentral

Betteridge Z, Tansley S, Shaddick G, Chinoy H, Cooper RG, New RP, Lilleker JB, Vencovsky J, Chazarain L, Danko K, Nagy-Vincze M, Bodoki L, Dastmalchi M, Ekholm L, Lundberg IE, McHugh N, contributors UK, (2019) Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun 101:48–55. https://doi.org/10.1016/j.jaut.2019.04.001CrossRefPubMedPubMedCentral

10.

Hall JC, Casciola-Rosen L, Samedy L-A, Werner J, Owoyemi K, Danoff SK, Christopher-Stine L (2013) Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care & Research 65(8):1307–1315. https://doi.org/10.1002/acr.21992CrossRef

11.

Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R (2016) Anti-melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care & Research 68(5):689–694. https://doi.org/10.1002/acr.22728CrossRef

12.

Motegi S-i, Sekiguchi A, Toki S, Kishi C, Endo Y, Yasuda M, Ikeuchi H, Sakairi T, Hara K, Yamaguchi K, Maeno T, Hiromura K, Ishikawa O (2019) Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease. European Journal of Dermatology 29(5):511–517. https://doi.org/10.1684/ejd.2019.3634CrossRefPubMed

13.

Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ, Fibrosis AEJACoIP, (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788–824. https://doi.org/10.1164/rccm.2009-040GLCrossRefPubMedPubMedCentral

14.

Yamaguchi K, Yamaguchi A, Kashiwagi C, Sawada Y, Taguchi K, Umetsu K, Oshima K, Uchida M, Suzuki M, Kono S, Takemura M, Masubuchi H, Kitahara S, Hara K, Maeno T, Motegi S-i, Muro Y, Sakairi T, Hisada T, Kurabayashi M (2018) Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies. Respir Med 140:1–5. https://doi.org/10.1016/j.rmed.2018.05.010CrossRefPubMed

15.

Jiang L, Wang Y, Peng Q, Shu X, Wang G, Wu X (2019) Serum YKL-40 level is associated with severity of interstitial lung disease and poor prognosis in dermatomyositis with anti-MDA5 antibody. Clin Rheumatol 38(6):1655–1663. https://doi.org/10.1007/s10067-019-04457-wCrossRefPubMed

16.

Huang K, Vinik O, Shojania K, Yeung J, Shupak R, Nimmo M, Avina-Zubieta JA (2019) Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review. Rheumatol Int 39(11):1971–1981. https://doi.org/10.1007/s00296-019-04398-2CrossRefPubMed

17.

Koga T, Fujikawa K, Horai Y, Okada A, Kawashiri S-y, Iwamoto N, Suzuki T, Nakashima Y, Tamai M, Arima K, Yamasaki S, Nakamura H, Origuchi T, Hamaguchi Y, Fujimoto M, Ishimatsu Y, Mukae H, Kuwana M, Kohno S, Eguchi K, Aoyagi K, Kawakami A (2012) The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology 51(7):1278–1284. https://doi.org/10.1093/rheumatology/ker518CrossRefPubMed

18.

Dias Junior AG, Sampaio NG, Rehwinkel J (2019) A balancing act: MDA5 in antiviral immunity and autoinflammation. Trends Microbiol 27(1):75–85. https://doi.org/10.1016/j.tim.2018.08.007CrossRefPubMed

19.

Muro Y, Sugiura K, Hoshino K, Akiyama M, Tamakoshi K (2011) Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan. Arthritis Research & Therapy 13 (6). https://doi.org/10.1186/ar3547

20.

Nishina N, Sato S, Masui K, Gono T, Kuwana M (2020) Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease. RMD Open 6 (2). https://doi.org/10.1136/rmdopen-2020-001202

21.

Gono T, Kawaguchi Y, Kuwana M, Sugiura T, Furuya T, Takagi K, Ichida H, Katsumata Y, Hanaoka M, Okamoto Y, Ota Y, Kataoka S, Yamanaka H (2012) HLA-DRB1*0101/*0405 is associated with susceptibility to anti-MDA5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum 64(10):S822–S822

22.

Rothwell S, Chinoy H, Lamb JA, Miller FW, Rider LG, Wedderburn LR, McHugh NJ, Mammen AL, Betteridge ZE, Tansley SL, Bowes J, Vencovsky J, Deakin CT, Danko K, Vidya L, Selva-O’Callaghan A, Pachman LM, Reed AM, Molberg O, Benveniste O, Mathiesen PR, Radstake T, Doria A, de Bleecker J, Lee AT, Hanna MG, Machado PM, Ollier WE, Gregersen PK, Padyukov L, O’Hanlon TP, Cooper RG, Lundberg IE, Myositis Genetics C (2019) Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups. Ann Rheum Dis 78(7):996–1002. https://doi.org/10.1136/annrheumdis-2019-215046CrossRefPubMedPubMedCentral

23.

Kochi Y, Kamatani Y, Kondo Y, Suzuki A, Kawakami E, Hiwa R, Momozawa Y, Fujimoto M, Jinnin M, Tanaka Y, Kanda T, Cooper RG, Chinoy H, Rothwell S, Lamb JA, Vencovsky J, Mann H, Ohmura K, Myouzen K, Ishigaki K, Nakashima R, Hosono Y, Tsuboi H, Kawasumi H, Iwasaki Y, Kajiyama H, Horita T, Ogawa-Momohara M, Takamura A, Tsunoda S, Shimizu J, Fujio K, Amano H, Mimori A, Kawakami A, Umehara H, Takeuchi T, Sano H, Muro Y, Atsumi T, Mimura T, Kawaguchi Y, Mimori T, Takahashi A, Kubo M, Kohsaka H, Sumida T, Yamamoto K (2018) Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. Ann Rheum Dis 77(4):602–611. https://doi.org/10.1136/annrheumdis-2017-212149CrossRefPubMed

24.

Cassius C, Amode R, Delord M, Battistella M, Poirot J, How-Kit A, Lepelletier C, Jachiet M, de Masson A, Frumholtz L, Cordoliani F, Boccara D, Lehmann-Che J, Wong J, Dubanchet S, Alberdi AJ, Merandet M, Bagot M, Bensussan A, Bouazia J-D, Le Buanec H (2020) MDA5(+) D dermatomyositis is associated with stronger skin type I interferon transcriptomic signature with upregulation of IFN-kappa transcript. Journal of Investigative Dermatology 140(6):1276–1279. https://doi.org/10.1016/j.jid.2019.10.020CrossRef

25.

Ono N, Kai K, Maruyama A, Sakai M, Sadanaga Y, Koarada S, Inoue T, Tada Y (2019) The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients. Rheumatology (Oxford) 58(5):786–791. https://doi.org/10.1093/rheumatology/key386CrossRef

26.

Pinal-Fernandez I, Casal-Dominguez M, Derfoul A, Pak K, Miller FW, Milisenda JC, Grau-Junyent JM, Selva-O’Callaghan A, Carrion-Ribas C, Paik JJ, Albayda J, Christopher-Stine L, Lloyd TE, Corse AM, Mammen AL (2020) Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis. Ann Rheum Dis 79(9):1234–1242. https://doi.org/10.1136/annrheumdis-2019-216599CrossRefPubMed

27.

Allenbach Y, Leroux G, Suarez-Calvet X, Preusse C, Gallardo E, Hervier B, Rigolet A, Hie M, Pehl D, Limal N, Hufnagl P, Zerbe N, Meyer A, Aouizerate J, Uzunhan Y, Maisonobe T, Goebel HH, Benveniste O, Stenzel W, French Myositis N (2016) Dermatomyositis with or without anti-melanoma differentiation-associated gene 5 antibodies: common interferon signature but distinct NOS2 expression. Am J Pathol 186(3):691–700. https://doi.org/10.1016/j.ajpath.2015.11.010CrossRefPubMed

28.

Horai Y, Koga T, Fujikawa K, Takatani A, Nishino A, Nakashima Y, Suzuki T, Kawashiri S-y, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Ida H, Kakugawa T, Sakamoto N, Ishimatsu Y, Mukae H, Hamaguchi Y, Fujimoto M, Kuwana M, Origuchi T, Kohno S, Kawakami A (2015) Serum interferon-alpha is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis. Mod Rheumatol 25(1):85–89. https://doi.org/10.3109/14397595.2014.900843CrossRefPubMed

29.

Zhang SH, Zhao Y, Xie QB, Jiang Y, Wu YK, Yan B (2019) Aberrant activation of the type I interferon system may contribute to the pathogenesis of anti-melanoma differentiation-associated gene 5 dermatomyositis. Br J Dermatol 180(5):1090–1098. https://doi.org/10.1111/bjd.16917CrossRefPubMed

30.

Gono T, Kaneko H, Kawaguchi Y, Hanaoka M, Kataoka S, Kuwana M, Takagi K, Ichida H, Katsumata Y, Ota Y, Kawasumi H, Yamanaka H (2014) Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology (Oxford) 53(12):2196–2203. https://doi.org/10.1093/rheumatology/keu258CrossRef

31.

Takada T, Ohashi K, Hayashi M, Asakawa K, Sakagami T, Kikuchi T, Sato S (2018) Role of IL-15 in interstitial lung diseases in amyopathic dermatomyositis with anti-MDA-5 antibody. Respir Med 141:7–13. https://doi.org/10.1016/j.rmed.2018.06.012CrossRefPubMed

32.

Ishikawa Y, Iwata S, Hanami K, Nawata A, Zhang M, Yamagata K, Hirata S, Sakata K, Todoroki Y, Nakano K, Nakayamada S, Satoh M, Tanaka Y (2018) Relevance of interferon-gamma in pathogenesis of life-threatening rapidly progressive interstitial lung disease in patients with dermatomyositis. Arthritis Res Ther 20(1):240. https://doi.org/10.1186/s13075-018-1737-2CrossRefPubMedPubMedCentral

33.

Chen M, Quan C, Diao L, Xue F, Xue K, Wang B, Li X, Zhu X, Zheng J, Cao H (2018) Measurement of cytokines and chemokines and association with clinical severity of dermatomyositis and clinically amyopathic dermatomyositis. Br J Dermatol 179(6):1334–1341. https://doi.org/10.1111/bjd.17079CrossRefPubMed

34.

Abe Y, Matsushita M, Tada K, Yamaji K, Takasaki Y, Tamura N (2017) Clinical characteristics and change in the antibody titres of patients with anti-MDA5 antibody-positive inflammatory myositis. Rheumatology (Oxford) 56(9):1492–1497. https://doi.org/10.1093/rheumatology/kex188CrossRef

35.

Chen Z, Cao M, Nieves Plana M, Liang J, Cai H, Kuwana M, Sun L (2013) Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis. Arthritis Care & Research 65(8):1316–1324. https://doi.org/10.1002/acr.21985CrossRef

36.

Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y, Takagi K, Baba S, Okamoto Y, Ota Y, Yamanaka H (2012) Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology 51(9):1563–1570. https://doi.org/10.1093/rheumatology/kes102CrossRefPubMed

37.

So H, Ip RWK, Wong VTL, Yip RML (2018) Analysis of anti-melanoma differentiation-associated gene 5 antibody in Hong Kong Chinese patients with idiopathic inflammatory myopathies: diagnostic utility and clinical correlations. International Journal of Rheumatic Diseases 21(5):1076–1081. https://doi.org/10.1111/1756-185x.13268CrossRefPubMed

38.

Ye S, Chen X-x, Lu X-y, Wu M-f, Deng Y, Huang W-q, Guo Q, Yang C-d, Gu Y-y, Bao C-d, Chen S-l (2007) Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol 26(10):1647–1654. https://doi.org/10.1007/s10067-007-0562-9CrossRefPubMed

39.

Tsuji H, Nakashima R, Hosono Y, Imura Y, Yagita M, Yoshifuji H, Hirata S, Nojima T, Sugiyama E, Hatta K, Taguchi Y, Katayama M, Tanizawa K, Handa T, Uozumi R, Akizuki S, Murakami K, Hashimoto M, Tanaka M, Ohmura K, Mimori T (2020) Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol 72(3):488–498. https://doi.org/10.1002/art.41105CrossRefPubMed

40.

Fujiki Y, Kotani T, Isoda K, Ishida T, Shoda T, Yoshida S, Takeuchi T, Makino S (2018) Evaluation of clinical prognostic factors for interstitial pneumonia in anti-MDA5 antibody-positive dermatomyositis patients. Mod Rheumatol 28(1):133–140. https://doi.org/10.1080/14397595.2017.1318468CrossRefPubMed

41.

Yamaguchi K, Yamaguchi A, Itai M, Kashiwagi C, Takehara K, Aoki S, Sawada Y, Taguchi K, Umetsu K, Oshima K, Uchida M, Takemura M, Hara K, Motegi S-I, Muro Y, Nakasatomi M, Sakairi T, Hiromura K, Kurabayashi M, Maeno T (2019) Clinical features of patients with anti-melanoma differentiation-associated gene-5 antibody-positive dermatomyositis complicated by spontaneous pneumomediastinum. Clin Rheumatol 38(12):3443–3450. https://doi.org/10.1007/s10067-019-04729-5CrossRefPubMed

42.

Zhou M, Ye Y, Yan N, Lian X, Bao C, Guo Q (2020) Noninvasive positive pressure ventilator deteriorates the outcome of pneumomediastinum in anti-MDA5 antibody-positive clinically amyopathic dermatomyositis. Clin Rheumatol 39(6):1919–1927. https://doi.org/10.1007/s10067-019-04918-2CrossRefPubMed

43.

Hozumi H, Fujisawa T, Nakashima R, Johkoh T, Sumikawa H, Murakami A, Enomoto N, Inui N, Nakamura Y, Hosono Y, Imura Y, Mimori T, Suda T (2016) Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease. Respir Med 121:91–99. https://doi.org/10.1016/j.rmed.2016.10.019CrossRefPubMed

44.

Zou J, Guo Q, Chi J, Wu H, Bao C (2015) HRCT score and serum ferritin level are factors associated to the 1-year mortality of acute interstitial lung disease in clinically amyopathic dermatomyositis patients. Clin Rheumatol 34(4):707–714. https://doi.org/10.1007/s10067-015-2866-5CrossRefPubMed

45.

Zuo Y, Ye L, Liu M, Li S, Liu W, Chen F, Lu X, Gordon P, Wang G, Shu X (2020) Clinical significance of radiological patterns of HRCT and their association with macrophage activation in dermatomyositis. Rheumatology (Oxford) 59(10):2829–2837. https://doi.org/10.1093/rheumatology/keaa034CrossRef

46.

Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Watanabe K, Aihara K, Oga T, Chin K, Nagai S, Mimori T, Mishima M (2011) HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med 105(9):1380–1387. https://doi.org/10.1016/j.rmed.2011.05.006CrossRefPubMed

47.

Chino H, Sekine A, Baba T, Iwasawa T, Okudela K, Takemura T, Itoh H, Sato S, Suzuki Y, Ogura T (2016) Radiological and pathological correlation in anti-MDA5 antibody-positive interstitial lung disease: rapidly progressive perilobular opacities and diffuse alveolar damage. Intern Med 55(16):2241–2246. https://doi.org/10.2169/internalmedicine.55.5774CrossRefPubMed

48.

Chino H, Sekine A, Baba T, Kitamura H, Iwasawa T, Okudela K, Takemura T, Itoh H, Sato S, Suzuki Y, Ogura T (2019) Interstitial lung disease with anti-melanoma differentiation-associated protein 5 antibody: rapidly progressive perilobular opacity. Intern Med 58(18):2605–2613. https://doi.org/10.2169/internalmedicine.2328-18CrossRefPubMedPubMedCentral

49.

Nishioka A, Tsunoda S, Abe T, Yoshikawa T, Takata M, Kitano M, Matsui K, Nakashima R, Hosono Y, Ohmura K, Mimori T, Sano H (2019) Serum neopterin as well as ferritin, soluble interleukin-2 receptor, KL-6 and anti-MDA5 antibody titer provide markers of the response to therapy in patients with interstitial lung disease complicating anti-MDA5 antibody-positive dermatomyositis. Mod Rheumatol 29(5):814–820. https://doi.org/10.1080/14397595.2018.1548918CrossRefPubMed

50.

Matsushita T, Mizumaki K, Kano M, Yagi N, Tennichi M, Takeuchi A, Okamoto Y, Hamaguchi Y, Murakami A, Hasegawa M, Kuwana M, Fujimoto M, Takehara K (2017) Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis. Br J Dermatol 176(2):395–402. https://doi.org/10.1111/bjd.14882CrossRefPubMed

51.

Endo Y, Koga T, Ishida M, Fujita Y, Tsuji S, Takatani A, Shimizu T, Sumiyoshi R, Igawa T, Umeda M, Fukui S, Nishino A, Kawashiri SY, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Kuwana M, Hosono Y, Mimori T, Kawakami A (2018) Recurrence of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis after long-term remission: a case report. Medicine (Baltimore) 97(26):e11024. https://doi.org/10.1097/MD.0000000000011024CrossRef

52.

Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, Masuda I, Tochimoto A, Baba S, Okamoto Y, Ota Y, Yamanaka H (2010) Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology (Oxford) 49(9):1713–1719. https://doi.org/10.1093/rheumatology/keq149CrossRef

53.

Xu Y, Yang CS, Li YJ, Liu XD, Wang JN, Zhao Q, Xiao WG, Yang PT (2016) Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis. Clin Rheumatol 35(1):113–116. https://doi.org/10.1007/s10067-015-3139-zCrossRefPubMed

54.

Kurasawa K, Arai S, Namiki Y, Tanaka A, Takamura Y, Owada T, Arima M, Maezawa R (2018) Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology (Oxford) 57(12):2114–2119. https://doi.org/10.1093/rheumatology/key188CrossRef

55.

Ito M, Kaise S, Suzuki S, Kazuta Y, Sato Y, Miyata M, Nishimaki T, Nakamura N, Kasukawa R (1999) Clinico-laboratory characteristics of patients with dermatomyositis accompanied by rapidly progressive interstitial lung disease. Clin Rheumatol 18(6):462–467. https://doi.org/10.1007/s100670050139CrossRefPubMed

56.

Yoshifuji H (2015) Biomarkers and autoantibodies of interstitial lung disease with idiopathic inflammatory myopathies. Clin Med Insights Circ Respir Pulm Med 9(Suppl 1):141–146. https://doi.org/10.4137/CCRPM.S36748CrossRefPubMed

57.

Kohno N, Akiyama M, Kyoizumi S, Hakoda M, Kobuke K, Yamakido M (1988) Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma. Jpn J Clin Oncol 18(3):203–216PubMed

58.

Bandoh S, Fujita J, Ohtsuki Y, Ueda Y, Hojo S, Tokuda M, Dobashi H, Kurata N, Yoshinouchi T, Kohno N, Takahara J (2000) Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis. Ann Rheum Dis 59(4):257–262. https://doi.org/10.1136/ard.59.4.257CrossRefPubMedPubMedCentral

59.

Ye Y, Fu Q, Wang R, Guo Q, Bao C (2019) Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease. J Clin Lab Anal 33(8):e22978. https://doi.org/10.1002/jcla.22978CrossRefPubMedPubMedCentral

60.

Wang K, Zhao J, Chen Z, Li T, Tan X, Zheng Y, Gu L, Guo L, Sun F, Wang H, Li J, Wang X, Riemekasten G, Ye S (2019) CD4+CXCR4+ T cells as a novel prognostic biomarker in patients with idiopathic inflammatory myopathy-associated interstitial lung disease. Rheumatology (Oxford) 58(3):511–521. https://doi.org/10.1093/rheumatology/key341CrossRef

61.

Suzuki J, Morimoto S, Amano H, Tokano Y, Takasaki Y, Hashimoto H (2001) Serum levels of interleukin 15 in patients with rheumatic diseases. J Rheumatol 28(11):2389–2391PubMed

62.

Zong M, Loell I, Lindroos E, Nader GA, Alexanderson H, Hallengren CS, Borg K, Arnardottir S, McInnes IB, Lundberg IE (2012) Effects of immunosuppressive treatment on interleukin-15 and interleukin-15 receptor alpha expression in muscle tissue of patients with polymyositis or dermatomyositis. Ann Rheum Dis 71(6):1055–1063. https://doi.org/10.1136/annrheumdis-2011-200495CrossRefPubMed

63.

Shimizu T, Koga T, Furukawa K, Horai Y, Fujikawa K, Okada A, Okamoto M, Endo Y, Tsuji S, Takatani A, Umeda M, Fukui S, Sumiyoshi R, Kawashiri SY, Iwamoto N, Igawa T, Ichinose K, Tamai M, Sakamoto N, Nakamura H, Origuchi T, Mukae H, Kuwana M, Kawakami A (2020) IL-15 is a biomarker involved in the development of rapidly progressive interstitial lung disease complicated with polymyositis/dermatomyositis. J Intern Med. https://doi.org/10.1111/joim.13154CrossRefPubMed

64.

Nara M, Komatsuda A, Omokawa A, Togashi M, Okuyama S, Sawada K, Wakui H (2014) Serum interleukin 6 levels as a useful prognostic predictor of clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease. Mod Rheumatol 24(4):633–636. https://doi.org/10.3109/14397595.2013.844390CrossRefPubMed

65.

Romero-Bueno F, Diaz Del Campo P, Trallero-Araguas E, Ruiz-Rodriguez JC, Castellvi I, Rodriguez-Nieto MJ, Martinez-Becerra MJ, Sanchez-Pernaute O, Pinal-Fernandez I, Solanich X, Gono T, Gonzalez-Gay MA, Plana MN, Selva-O’Callaghan A, group M, (2020) Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum 50(4):776–790. https://doi.org/10.1016/j.semarthrit.2020.03.007CrossRefPubMed

66.

Chen Z, Wang X, Ye S (2019) Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease. N Engl J Med 381(3):291–293. https://doi.org/10.1056/NEJMc1900045CrossRefPubMed

67.

So H, Wong VTL, Lao VWN, Pang HT, Yip RML (2018) Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis. Clin Rheumatol 37(7):1983–1989. https://doi.org/10.1007/s10067-018-4122-2CrossRefPubMed

68.

Zou J, Li T, Huang X, Chen S, Guo Q, Bao C (2014) Basiliximab may improve the survival rate of rapidly progressive interstitial pneumonia in patients with clinically amyopathic dermatomyositis with anti-MDA5 antibody. Ann Rheum Dis 73(8):1591–1593. https://doi.org/10.1136/annrheumdis-2014-205278CrossRefPubMed

69.

Koichi Y, Aya Y, Megumi U, Shunichi K, Masafumi S, Hiroaki M, Masahiko K, Shinsuke K, Manabu U, Kenichiro H, Fumiaki A, Nozomi A, Toshitaka M, Masayoshi Y, Chikako K, Yoshinao M, Tatsuo S, Masahiko K (2017) A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment. Mod Rheumatol 27(3):536–540. https://doi.org/10.3109/14397595.2015.1014140CrossRefPubMed

70.

Abe Y, Kusaoi M, Tada K, Yamaji K, Tamura N (2020) Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy. Rheumatology (Oxford) 59(4):767–771. https://doi.org/10.1093/rheumatology/kez357CrossRef

71.

Kagawa H, Tsujino K, Yamamoto Y, Iwai A, Hara R, Matsuki T, Fukushima K, Oshitani Y, Yoshimura K, Miki M, Miki K, Kitada S, Mori M, Kida H (2020) Acute lung injury after plasma exchange in a patient with anti-MDA5 antibody-positive, rapidly progressive, interstitial lung disease: a case report. Respir Med Case Rep 29:101016. https://doi.org/10.1016/j.rmcr.2020.101016CrossRefPubMedPubMedCentral

72.

Okabayashi H, Ichiyasu H, Hirooka S, Akaike K, Kojima K, Jodai T, Sakamoto Y, Ideguchi H, Hamada S, Yoshida C, Hirosako S, Okamoto S, Kohrogi H (2017) Clinical effects of direct hemoperfusion using a polymyxin B-immobilized fiber column in clinically amyopathic dermatomyositis-associated rapidly progressive interstitial pneumonias. BMC Pulm Med 17(1):134. https://doi.org/10.1186/s12890-017-0479-2CrossRefPubMedPubMedCentral

73.

Li T, Guo L, Chen Z, Gu L, Sun F, Tan X, Chen S, Wang X, Ye S (2016) Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis. Sci Rep 6:33226. https://doi.org/10.1038/srep33226CrossRefPubMedPubMedCentral

74.

Leclair V, Labirua-Iturburu A, Lundberg IE (2018) Successful lung transplantation in a case of rapidly progressive interstitial lung disease associated with antimelanoma differentiation-associated gene 5 antibodies. J Rheumatol 45(4):581–583. https://doi.org/10.3899/jrheum.171047CrossRefPubMed

75.

Huang K, Levy RD, Avina-Zubieta JA (2020) Successful lung transplant in rapid progressive interstitial lung disease associated with anti-melanoma differentiation associated gene 5. Rheumatology (Oxford) 59(8):2161–2163. https://doi.org/10.1093/rheumatology/keaa032CrossRef

Title: Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis
Authors: Wanlong Wu
Li Guo
Yakai Fu
Kaiwen Wang
Danting Zhang
Wenwen Xu
Zhiwei Chen
Shuang Ye
Publication date: 01-04-2021
Publisher: Springer US
Keywords: Dermatomyositis
Biomarkers
Published in: Clinical Reviews in Allergy & Immunology / Issue 2/2021
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI: https://doi.org/10.1007/s12016-020-08822-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2021

The Roles of Orphan G Protein-Coupled Receptors in Autoimmune Diseases

Cytoskeletal Organization and Cell Polarity in the Pathogenesis of Crohn’s Disease

The AGE-RAGE Axis and RAGE Genetics in Chronic Obstructive Pulmonary Disease

Resolving Clinical Phenotypes into Endotypes in Allergy: Molecular and Omics Approaches

Use of Ultraviolet Blood Irradiation Against Viral Infections

Anti-inflammatory Action of Statins in Cardiovascular Disease: the Role of Inflammasome and Toll-Like Receptor Pathways

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials